BiotechTV - News

Dr. Bourla looks back on Pfizers $43B acquisition of Seagen and the company's more recent license of a VEGF x PD1 bispecific. He highlights ASCO data for BRAFTOVI, vepdegestrant, and XTANDI. Plus, his thoughts on the hot button issues of China biotech and biopharma's public reputation.

He gives his thoughts on the competitiveness of Teva's TL1A, and highlights other pipeline programs that biotech investors might look at. Plus, how the company is doing transitioning its investor base from generic drug focused investors to biotech.

He highlights Teva's improved financial position, its commercial prowess, and the pipeline assets to watch, including a TL1A that biotech investors have been watching closely.

He describes key presentations for Enhertu, TRODELVY, immunotherapy medicines, and a couple key biomarkers to watch.

He describes how policy, macro, and events have been affecting trading in biotech stocks lately. Plus, his thoughts on the pull back of generalists from the sector.

He shares his overall thoughts on the biotech market, and discusses gene therapies, RNA editing, and cell therapy.

CEO Ram Aiyar describes Korro's 'OPERA' platform and explains why he thinks it is differentiated from others in the field. He previews the first data announcement that will happen later this year and discusses other work, including with the company's partner Novo Nordisk.

CEO Sanjay Shukla describes the science behind tRNA synthetase biology and how aTyr is leveraging it against inflammatory and fibrotic diseases, especially pulmonary disease. He sets up the phase 3 for Efzofitimod in pulmonary sarcoidosis, and also pending data in systemic sclerosis.

He describes where he sees AXPAXLI fitting into the treatment paradigm, and shares an update on the SOL-1 and SOL-R studies - including the rationale for recent changes to them. Plus an update on the NPDR indication.

He describes some of the discussions he is having at the conference, discusses the difference between how large companies he covers are handling volatility vs smaller ones, and offers his take on the prospects for M&A.

He describes the science behind Cidara's Cloudbreak Drug-Fc conjugates, which might have uniform efficacy regardless of how the flu changes each season. Plus, a preview of next month's readout, and how FDA discussions around this have been.

CEO Andree Blaukat describes TessellateBio's focus on synthetic lethality and the science behind this lead area they have partnered with Boehring Ingelheim on, which seeks to interrupt some cancers' ability to harness telomeres to continuously replicate. The deal is potentially work in excess of €500 million. Plus addition programs, including one targeting SKP2.

CEO Arndt Schottelius describes the rationale behind the KnotBody platform and the company's future plans to develop them against things like inflammatory diseases such as atopic dermatitis and inflammatory bowel disease.

CEO Alvin Luk and CTO TJ Cradick explain how the company's Cas12 and 13 programs are different than Cas9, and they discuss the DMD presentation and how this program differs from the current microdystrophin product that is on the market. Plus, RNA editing programs targeting neovascular age-related macular degeneration and MECP2 Duplication Syndrome (MDS), and a DNA program targeting ALS.

He talks about new capsids Dyno announced at this years' conference and the science behind getting them to specific places in the body. Plus, the company's new 'Frontiers Program' and a Genetic Agency Technology Conference coming up in November.

As published in NEJM today , UPenn's Kiran Musunuru describes how the team used base editing in a matter of months to treat an infant with CPS1 deficiently, and his thoughts on what the learnings of this case are for drug development.

CEO Rodolphe Clerval walks us through Coave's "ALIGATER' ligand technology and describes the importance of the cerebrospinal administered program. Plus, comments on the company's IV program for CNS conditions, and a recent €32 million series A.

CEO Jane Osbourn describes Alchemab's platform, which looks for people who are resilient to disease and then sequences them to understand why, and discusses this week's deal and the company's prior one with Lilly as well.

ProQR Co-Founder & CSO Gerard Platenburg describes the company's RNA editing platform and the journey he has seen this field go through over time. Plus, updates on programs for cholestatic diseases, Rhett Syndrome, and MASH.

CEO Peter Anastasiou describes the importance of capsid design and how Caspida is developing its own gene therapies for CNS conditions. A first program recently had its IND cleared.

CEO Erik Wiklund and CTO Thomas Hansen describe what circular RNA is, and explain their groundbreaking work where they discovered circular RNA in humans over a decade ago. They discuss potential use cases, including using it for in-vivo CAR-T, something that has been talked about a lot at this year's conference.

He discusses the clinical programs, delivery vehicle advances, and safety improvements to watch for this year as the field of cell and gene therapies progresses.

Inductive Bio raised a $25M series A last week to continue its work utilizing AI to help drug developers in discovery understand a small molecule's ADMET properties before it is synthesized.

Co-Founder & President Jacob Kimmel and Head of Operations Cathy O'Hare describe the scientific approach and how it benefits from the crossroads of genomics and machine learning. Plus, which indications the company plans to start out in clinically.

He describes the current environment for life sciences in Europe and how far it has come over the last ten years. Plus, his thoughts on the value of being local for uncovering opportunities, and the state of the capital markets.